AT&T's second-quarter results have exceeded expectations, driven by robust growth in 5G and fiber subscribers.

GM beat Q2 2025 earnings expectations but shares fell 7% due to $1.1 billion tariff impact and margin compression concerns.

Thermo Fisher Scientific's second quarter of 2025 demonstrated a 3% revenue increase to $10.85 billion, slightly surpassing expectations.

Boston Scientific's Q2 2025 results exceeded expectations, with net sales of $5.061 billion and adjusted EPS of $0.75.

Abivax shares surged over 400% in premarket trading after announcing positive Phase 3 results for its ulcerative colitis drug ...

These three high-yield dividend aristocrats not only deliver dependable income but also offer resilient fundamentals against ...